Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma

被引：9

作者：

Abe, Kentaro ^{[1
,2
]}

Maeda-Minami, Ayako ^{[1
]}

Ishizu, Taku ^{[1
]}

Iwata, Shintaro ^{[3
]}

Kobayashi, Eisuke ^{[3
]}

Shimoi, Tatsunori ^{[4
]}

Kawano, Yohei ^{[1
]}

Hashimoto, Hironobu ^{[2
]}

Yamaguchi, Masakazu ^{[5
]}

Furukawa, Tetsuya ^{[2
]}

Miyazaki, Satoru ^{[1
]}

Mano, Yasunari ^{[1
]}

机构：

[1] Tokyo Univ Sci, Fac Pharmaceut Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan

[2] Natl Canc Ctr, Dept Pharm, Tokyo, Japan

[3] Natl Canc Ctr, Dept Musculoskeletal Oncol, Tokyo, Japan

[4] Natl Canc Ctr, Dept Med Oncol, Tokyo, Japan

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pharm, Tokyo, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 02期

关键词：

High-dose methotrexate (HD-MTX); hepatic dysfunction; osteosarcoma; clinical study; PLASMA METHOTREXATE; SERUM CREATININE; PHARMACOKINETICS; CHEMOTHERAPY; CHILDREN; ASSOCIATION; CLEARANCE; PROGNOSIS; ARTHRITIS; LYMPHOMA;

D O I：

10.21873/anticanres.15565

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: High-dose methotrexate (HD-MTX) is widely used to treat osteosarcoma. However, some patients develop hepatic toxicity, leading to dose modification and delays in the scheduled chemotherapy. The present study aimed to identify the risk factors of hepatotoxicity in patients with osteosarcoma. Patients and Methods: We conducted a retrospective study of patients with osteosarcoma treated with HD-MTX between January 2014 and June 2020 at the National Cancer Center Hospital, Japan. The risk factors for MTX-induced hepatotoxicity (>= grade 3) were identified using multivariate logistic regression analysis. Results: The final analysis included 88 courses of 36 patients. Hepawtoxicity occurred in 51 (58.0%) of the 88 courses. Female sex, MTX dose (>102 g/m(2)), and serum calcium concentration (>9.3 mg/dl) were identified as risk factors for HD-MTX-induced hepatotoxicity. Conclusion: Identifying the risk factors of HD-MTX-induced hepatotoxicity may contribute to improvements in the safety and management of HD-MTX therapy.

引用

页码：1043 / 1050

页数：8

共 36 条

[1] Concomitant Use of High-dose Methotrexate and Glycyrrhizin Affects Pharmacokinetics of Methotrexate, Resulting in Hepatic Toxicity [J].

Abe, Kentaro ;

Higurashi, Tsukasa ;

Takahashi, Mio ;

Maeda-Minami, Ayako ;

Kawano, Yohei ;

Miyazaki, Satoru ;

Mano, Yasunari .

IN VIVO, 2021, 35 (04) :2163-2169

[2] Roles of Parathyroid Hormone-Related Protein (PTHrP) and Its Receptor (PTHR1) in Normal and Tumor Tissues: Focus on Their Roles in Osteosarcoma [J].

Al-Khan, Awf A. ;

Al Balushi, Noora R. ;

Richardson, Samantha J. ;

Danks, Janine A. .

FRONTIERS IN VETERINARY SCIENCE, 2021, 8

[3] Ionized calcium [J].

Baird, Geoffrey S. .

CLINICA CHIMICA ACTA, 2011, 412 (9-10) :696-701

[4] Effectiveness and Toxicity of Methotrexate in Juvenile Idiopathic Arthritis: Comparison of 2 Initial Dosing Regimens [J].

Becker, Mara L. ;

Rose, Carlos D. ;

Cron, Randy Q. ;

Sherry, David D. ;

Bilker, Warren B. ;

Lautenbach, Ebbing .

JOURNAL OF RHEUMATOLOGY, 2010, 37 (04) :870-875

[5]

Buuren S van., 2021, Package "mice

[6] Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer [J].

Cheng, K. K. -F. .

EUROPEAN JOURNAL OF CANCER CARE, 2008, 17 (03) :306-311

[7] Serum calcium, albumin and tumor stage in cutaneous malignant melanoma [J].

Datta, Mridul ;

Savage, Paul ;

Lovato, James ;

Schwartz, Gary G. .

FUTURE ONCOLOGY, 2016, 12 (19) :2205-2214

[8] Review of Osteosarcoma and Current Management [J].

Durfee R.A. ;

Mohammed M. ;

Luu H.H. .

Rheumatology and Therapy, 2016, 3 (2) :221-243

[9] Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data [J].

Fukuhara, K. ;

Ikawa, K. ;

Morikawa, N. ;

Kumagai, K. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (06) :677-684

[10] METHOTREXATE PHARMACOKINETICS AND PROGNOSIS IN OSTEOSARCOMA [J].

GRAF, N ;

WINKLER, K ;

BETLEMOVIC, M ;

FUCHS, N ;

BODE, U .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) :1443-1451

← 1 2 3 4 →